Share Name Share Symbol Market Type Share ISIN Share Description
Widecells Group LSE:WDC London Ordinary Share GB00BD060S65 ORD GBP0.0025
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 2.65p 0 08:00:00
Bid Price Offer Price High Price Low Price Open Price
2.60p 2.70p 2.65p 2.65p 2.65p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.05 -2.81 -5.00 1.7

Widecells (WDC) Latest News

More Widecells News
Widecells Takeover Rumours

Widecells (WDC) Share Charts

1 Year Widecells Chart

1 Year Widecells Chart

1 Month Widecells Chart

1 Month Widecells Chart

Intraday Widecells Chart

Intraday Widecells Chart

Widecells (WDC) Discussions and Chat

Widecells Forums and Chat

Date Time Title Posts
18/7/201818:14WideCells Group228
14/6/201812:39Widecells Interview and Q&A-
05/4/201812:01Widecells Group INTERVIEW-
26/3/201808:34INTERVIEW: Widecells Group PLC1
22/8/201721:41Revenue lift off1

Add a New Thread

Widecells (WDC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Widecells trades in real-time

Widecells (WDC) Top Chat Posts

DateSubject
19/7/2018
09:20
Widecells Daily Update: Widecells Group is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker WDC. The last closing price for Widecells was 2.65p.
Widecells Group has a 4 week average price of 2.60p and a 12 week average price of 2.60p.
The 1 year high share price is 15p while the 1 year low share price is currently 2.60p.
There are currently 64,821,010 shares in issue and the average daily traded volume is 201,521 shares. The market capitalisation of Widecells Group is £1,717,756.77.
25/6/2018
22:18
rampair: After a few years you could reward yourself quite well if you’d built your business, your share price would respond.
15/6/2018
07:42
longshanks: Do you work for Align, Imhustdandy?I read the note, and it is great that they think the company is worth as much as they do, but there is very little content to what they write.The release of an RNS about a "research" note by a paid hack is also rather odd. Seems like a case of Fake News to me.Clearly the company needs to raise more cash this year and they are keen to get the share price higher to minimise dilution. However the best way to demonstrate a prospective 2020 PER of 1.1 is to actually deliver some revenue streams. Sad too for shareholders that some of their valuable investment cash is being spent in this way.The only highlight is that they have a couple of fund managers interested enough to put some pin money into this. I suspect it is just that, a little bit of risk money to give them a chance on the 100:1 runner at Haydock.For me though, it is still a case of: Avoid.
14/6/2018
18:47
hobnob1: Why on earth does this board think it should be paid? They have delivered no profits, no revenue and have crashed the share price. If they want a job, go and apply for one at a profitable company.
06/6/2018
16:19
balance1: The Chairman's letter fails to mention the massive destruction of shareholder value through the collapse of the share price. You would have thought the Chairman's review would explain why the company completely ran out of money, despite being fully funded up to its headroom limits, and how he will ensure this doesn't happen again.
20/3/2018
14:46
237gmoney: Hi All, I'm new here. Can anyone tell me who the Reinsurance partners are on the Cell Plan? I can't find the name of the company anywhere.... Only that the cellplan costs £170 a year and £50 of this will go towards Reinsurance costs. They say it is a market leading Reinsurer but if you tell me the name I can be the judge of that. Also if we knew who it was it would be a big selling point for the company. I like the company although the share price has taken a little knock last 6 weeks? Cashflow issues?
31/10/2017
10:03
hobnob1: timbo003, I have a couple of questions if you are going 1) They are saying revenue is the big story now, so how much revenue has been brought in so far? How much revenue do they think will come in over the next six months? Will the company be providing regular updates so shareholders can track this 2) The company has developed enormously over the last 12 months, but the share price hasn't gone anywhere, and there are virtually no buyers of the stock. Why is this? Agree with pranchalee, this could be a really special company. Just wanting to understand how quickly they can translate all this corporate development into shareholder return. So far the stock has been pretty disappointing.
26/10/2017
13:32
pranchalee: Awards and running marathons are all very well but how about getting the share price moving
17/10/2017
18:32
nohead: MM, yes I have met these guys and really like the company. They are smart and ambitious. They are at the stage of focussing 100% on building positive cash flow, and then translating that into share price performance. I think they will do both.
25/9/2017
10:11
iphone8: A very interesting new presentation has gone up on the Widecells website this morning. It goes into far more detail on revenue growth than any previous presentations or research notes. The great thing about the company is that it is providing a range of services to the fast-growing stem cell industry, but it is not a stem cell technology company itself, so it doesn’t carry that risk.There are now five different engines of revenue growth in the company: the stem cell insurance product, the stem cell storage facility, stem cell research services, stem cell education and a cell related detail product. Working through the presentation numbers (and making a few guesstimates) It looks like the company should make around £2m in “Year 1”, £5m in year 2, and £8m+ in year 3. It is not clear when “year 1” starts. But from other RNSs, Year 1 should be starting about now, or may have already started. There are some hints at cost of sales in the company’s margin estimates, but we don’t know how overall costs will rise. However, from these figures, it is a fair bet that the company will break even in 2018, possibly in the first half, and start turning a substantial profit in 2019. The presentation lacked any kind of peer group analysis showing the valuation of similar-style high growth start-ups on the LSE. However it is likely that these will show valuations of a multiple of Widecell’s trifling £8m valuation, especially when it gets into profit. As these various revenue streams “go live”, the market should start to pick up on this, especially if the company now starts to turn its attention to an aggressive share promotion programme. They could probably do with updating their broker research soon, as the last one is already looking rather dated. If these revenues come through, then the share price ought to re-rate by a multiple over the next 12 month, as the current market cap is so tiny Great to see the company coming out punching.
Widecells share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180719 23:19:18